ADR News Bulletin 2023 May (Volume 25 Number 1)
Bulletin Highlights:
- Analysis of adverse event reports with COVID-19 therapeutics for the treatment or prophylaxis of COVID-19
- Analysis of adverse event reports for health products for year 2022
- Analysis of COVID-19 vaccine adverse event reports for year 2022
- High-dose vitamin B6 and risk of peripheral neuropathy
- Navigation made easy – explore HSA’s website for adverse event reporting and safety information related to health products
Click on the link below to download the issue in pdf:
ADR_News_May2023_Vol25_No12519 KB
New drugs approved in 2022:
Healthcare professionals are encouraged to report all serious and non-serious
suspected adverse drug reactions (ADRs) with the use of new drugs. Your active
participation in the ADR monitoring programme will provide valuable support to
the post-marketing surveillance on drug safety.
Click on the link below to download the issue in pdf:
New Drugs Approved for 2022289 KB
Healthcare professional, Industry member, Therapeutic Products
Published:
Adverse Drug Reaction News Bulletins
11 Jan 2024
Doctors, dentists and pharmacists can claim continuing education points for reading each issue of the HSA ADR News Bulletin. Doctors can apply for one non-core Continuing Medical Education (CME) point under category 3A, dentists can apply for one Continuing Professional Education (CPE) point under category 3A and pharmacists can apply for one patient-care Continuing Professional Education (CPE) point under category 3A per issue of the bulletin. Each issue of the bulletin is valid for two years.